Halozyme Therapeutics HALO Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's total current liabilities?
- Halozyme Therapeutics (HALO) reported total current liabilities of $363.21M in Q1 2026.
- How has Halozyme Therapeutics's total current liabilities changed year-over-year?
- Halozyme Therapeutics's total current liabilities increased by 141.5% year-over-year, from $150.38M to $363.21M.
- What is the long-term trend for Halozyme Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's total current liabilities has grown at a -15.9% compound annual growth rate (CAGR), from $421.39M to $177.09M.
- What does total current liabilities mean?
- The total amount of debt and obligations the company must pay within one year.
- How do you interpret total current liabilities?
- An increase relative to current assets may signal liquidity pressure, while a decrease improves the current ratio.
- How does total current liabilities compare across companies?
- Used in the current ratio to compare short-term financial health against industry peers.